Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

BMS launches hepatitis C pill Daklinza in the UK

Will be offered as a combination treatment with Gilead's Solvadi

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

- PMLiVE

FDA approves BMS/Pfizer’s Eliquis in DVT and PE

New blood clot indication puts drug on a level with rival oral anticoagulants

Bristol Myers Squibb logo

BMS and Celgene to research cancer immunotherapy combo

Companies will study combination of nivolumab and Abraxane

Bristol-Myers Squibb (BMS) building

BMS creates US academic tie-up to foster biopharma research

Partnership with investment firm could also boost its pipeline

- PMLiVE

European licence for BMS/Pfizer’s Eliquis in DVT and PE

Anticoagulant catches up with Bayer's Xarelto and Boehringer's Pradaxa

- PMLiVE

This month in 1989: the creation of Bristol-Myers Squibb

The emergence of a company with a new focus on healthcare and research

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

- PMLiVE

Cancer drug nivolumab wins PD1 inhibitor race to market

BMS and Ono’s skin cancer treatment approved in Japan under trade name Opdivo

Bristol-Myers Squibb (BMS) building

BMS to publish full clinical study reports in transparency drive

Partners with Duke University to grant access back to 2008

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links